Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE)...
Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness